These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 22129499

  • 1. Growth of a solitary pulmonary nodule after 6years diagnosed as oncocytic carcinoid tumour with a high 18-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography-computed tomography (PET-CT).
    Turan O, Ozdogan O, Gurel D, Onen A, Kargi A, Sevinc C.
    Clin Respir J; 2013 Jan; 7(1):e1-5. PubMed ID: 22129499
    [Abstract] [Full Text] [Related]

  • 2. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
    Bryant AS, Cerfolio RJ.
    Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
    Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR.
    Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
    [Abstract] [Full Text] [Related]

  • 6. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours.
    Krüger S, Buck AK, Blumstein NM, Pauls S, Schelzig H, Kropf C, Schumann C, Mottaghy FM, Hombach V, Reske SN.
    J Intern Med; 2006 Dec; 260(6):545-50. PubMed ID: 17116005
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of primary pulmonary carcinoid tumors using FDG PET.
    Erasmus JJ, McAdams HP, Patz EF, Coleman RE, Ahuja V, Goodman PC.
    AJR Am J Roentgenol; 1998 May; 170(5):1369-73. PubMed ID: 9574618
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bronchogenic carcinoid tumours that are 18F-fluorodeoxyglucose avid on positron emission tomography.
    Hunt BM, Horton MP, Vallières E.
    Eur J Cardiothorac Surg; 2014 Mar; 45(3):527-30. PubMed ID: 24047710
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas.
    Uhlén N, Grundberg O, Jacobsson H, Sundin A, Dobra K, Sánchez-Crespo A, Axelsson R, Kölbeck KG.
    Clin Nucl Med; 2016 Apr; 41(4):263-7. PubMed ID: 26828139
    [Abstract] [Full Text] [Related]

  • 19. Overestimated value of (18)F-FDG PET/CT to diagnose pulmonary nodules: Analysis of 298 patients.
    Li S, Zhao B, Wang X, Yu J, Yan S, Lv C, Yang Y.
    Clin Radiol; 2014 Aug; 69(8):e352-7. PubMed ID: 24877581
    [Abstract] [Full Text] [Related]

  • 20. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
    Collaud S, Lardinois D, Tischler V, Steinert HC, Stahel R, Weder W.
    Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.